Document Detail


Chemoimmunotherapy: reengineering tumor immunity.
MedLine Citation:
PMID:  23389507     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cancer chemotherapy drugs have long been considered immune suppressive. However, more recent data indicate that some cytotoxic drugs effectively treat cancer in part by facilitating an immune response to the tumor when given at the standard dose and schedule. These drugs induce a form of tumor cell death that is immunologically active, thereby inducing an adaptive immune response specific for the tumor. In addition, cancer chemotherapy drugs can promote tumor immunity through ancillary and largely unappreciated immunologic effects on both the malignant and normal host cells present within the tumor microenvironment. These more subtle immunomodulatory effects are dependent on the drug itself, its dose, and its schedule in relation to an immune-based intervention. The recent approvals of two new immune-based therapies for prostate cancer and melanoma herald a new era in cancer treatment and have led to heightened interest in immunotherapy as a valid approach to cancer treatment. A detailed understanding of the cellular and molecular basis of interactions between chemotherapy drugs and the immune system is essential for devising the optimal strategy for integrating new immune-based therapies into the standard of care for various cancers, resulting in the greatest long-term clinical benefit for cancer patients.
Authors:
Gang Chen; Leisha A Emens
Related Documents :
24134337 - Clinical characteristics and prostate-specific antigen kinetics of prostate cancer dete...
21649577 - Present and future of pi3k pathway inhibition in cancer: perspectives and limitations.
24982717 - Endovascular therapy for acute stroke in patients with cancer.
23457597 - Bioactivity-guided identification and cell signaling technology to delineate the lactat...
15998627 - Cancer internet search activity on a major search engine, united states 2001-2003.
9353677 - Environmental exposure, social class, and cancer risk.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review     Date:  2013-02-07
Journal Detail:
Title:  Cancer immunology, immunotherapy : CII     Volume:  62     ISSN:  1432-0851     ISO Abbreviation:  Cancer Immunol. Immunother.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-12     Completed Date:  2013-04-12     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  8605732     Medline TA:  Cancer Immunol Immunother     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  203-16     Citation Subset:  IM    
Affiliation:
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231-1000, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / therapeutic use*
CD4-Positive T-Lymphocytes / drug effects,  immunology
CD8-Positive T-Lymphocytes / drug effects,  immunology
Clinical Trials as Topic
Dendritic Cells / drug effects,  immunology
Humans
Immunotherapy / methods*
Mice
Neoplasms / drug therapy,  therapy*
Tumor Microenvironment / drug effects,  immunology
Grant Support
ID/Acronym/Agency:
P50 CA088843/CA/NCI NIH HHS; P50CA88843/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Short-Term Predictive Validity of the Static-99 and Static-99-R for Indigenous and Nonindigenous Aus...
Next Document:  Spin-orbit coupling in quantum gases.